GABRIEL OLIVEIRA SAWAKUCHI
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Linear Energy Transfer | 11 | 2019 | 105 | 3.450 |
Why?
|
| Protons | 16 | 2022 | 483 | 3.230 |
Why?
|
| Radiometry | 15 | 2021 | 1017 | 2.440 |
Why?
|
| Carbon | 6 | 2021 | 164 | 2.010 |
Why?
|
| Proton Therapy | 16 | 2022 | 1638 | 1.630 |
Why?
|
| Monte Carlo Method | 12 | 2019 | 704 | 1.570 |
Why?
|
| DNA Damage | 5 | 2024 | 1988 | 1.350 |
Why?
|
| Aluminum Oxide | 4 | 2014 | 14 | 1.300 |
Why?
|
| Luminescent Measurements | 3 | 2012 | 159 | 1.130 |
Why?
|
| Radiation Dosage | 7 | 2018 | 1043 | 1.050 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2024 | 366 | 1.000 |
Why?
|
| Photons | 5 | 2021 | 537 | 0.970 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2024 | 78 | 0.950 |
Why?
|
| Particle Accelerators | 4 | 2017 | 362 | 0.930 |
Why?
|
| Phantoms, Imaging | 10 | 2020 | 1330 | 0.920 |
Why?
|
| Microscopy, Confocal | 2 | 2016 | 674 | 0.900 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 3 | 2024 | 437 | 0.900 |
Why?
|
| Magnetic Fields | 3 | 2019 | 33 | 0.850 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 8 | 2024 | 2453 | 0.820 |
Why?
|
| Radiotherapy, High-Energy | 4 | 2013 | 303 | 0.800 |
Why?
|
| Luminescence | 3 | 2019 | 45 | 0.650 |
Why?
|
| Radiation Tolerance | 5 | 2024 | 636 | 0.640 |
Why?
|
| DNA End-Joining Repair | 1 | 2019 | 92 | 0.640 |
Why?
|
| Homologous Recombination | 1 | 2019 | 187 | 0.620 |
Why?
|
| Diamond | 1 | 2017 | 3 | 0.610 |
Why?
|
| Electrical Equipment and Supplies | 1 | 2017 | 11 | 0.610 |
Why?
|
| Algorithms | 5 | 2016 | 3922 | 0.590 |
Why?
|
| Genes, BRCA1 | 2 | 2019 | 398 | 0.590 |
Why?
|
| Fluorescent Dyes | 1 | 2019 | 468 | 0.580 |
Why?
|
| Radiotherapy | 4 | 2019 | 1863 | 0.570 |
Why?
|
| Cell Death | 1 | 2019 | 689 | 0.560 |
Why?
|
| Absorption, Radiation | 1 | 2016 | 10 | 0.540 |
Why?
|
| Time-Lapse Imaging | 1 | 2016 | 22 | 0.530 |
Why?
|
| Radiotherapy, Image-Guided | 6 | 2024 | 340 | 0.520 |
Why?
|
| Optical Phenomena | 2 | 2012 | 26 | 0.520 |
Why?
|
| Fluorescence | 1 | 2016 | 199 | 0.520 |
Why?
|
| Radiosurgery | 2 | 2023 | 1378 | 0.510 |
Why?
|
| Water | 6 | 2017 | 384 | 0.420 |
Why?
|
| Neoplasms, Experimental | 1 | 2016 | 790 | 0.410 |
Why?
|
| Heavy Ions | 1 | 2011 | 1 | 0.410 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2020 | 7963 | 0.390 |
Why?
|
| Models, Theoretical | 4 | 2019 | 809 | 0.370 |
Why?
|
| Radiotherapy Dosage | 11 | 2024 | 4002 | 0.360 |
Why?
|
| DNA, Neoplasm | 1 | 2016 | 1972 | 0.360 |
Why?
|
| Cell Survival | 3 | 2021 | 3075 | 0.340 |
Why?
|
| Thermoluminescent Dosimetry | 2 | 2019 | 74 | 0.330 |
Why?
|
| Thorax | 2 | 2019 | 231 | 0.290 |
Why?
|
| Calibration | 3 | 2019 | 346 | 0.270 |
Why?
|
| Relative Biological Effectiveness | 3 | 2022 | 226 | 0.270 |
Why?
|
| Computer Simulation | 5 | 2018 | 1573 | 0.250 |
Why?
|
| Sulfoxides | 1 | 2024 | 22 | 0.240 |
Why?
|
| Cell Line, Tumor | 4 | 2024 | 14888 | 0.240 |
Why?
|
| Electrons | 3 | 2017 | 187 | 0.230 |
Why?
|
| Scattering, Radiation | 3 | 2010 | 334 | 0.230 |
Why?
|
| Head | 2 | 2020 | 249 | 0.220 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 5567 | 0.220 |
Why?
|
| Alpha Particles | 2 | 2023 | 26 | 0.220 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2024 | 7792 | 0.220 |
Why?
|
| Rad51 Recombinase | 2 | 2022 | 125 | 0.210 |
Why?
|
| Morpholines | 1 | 2024 | 296 | 0.210 |
Why?
|
| Boron Neutron Capture Therapy | 1 | 2022 | 13 | 0.210 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2024 | 338 | 0.210 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2017 | 917 | 0.200 |
Why?
|
| Pancreatic Neoplasms | 4 | 2023 | 5248 | 0.190 |
Why?
|
| Germ-Line Mutation | 3 | 2021 | 1102 | 0.190 |
Why?
|
| DNA Breaks, Double-Stranded | 2 | 2019 | 327 | 0.180 |
Why?
|
| Time Factors | 4 | 2019 | 13135 | 0.170 |
Why?
|
| Optically Stimulated Luminescence Dosimetry | 1 | 2019 | 21 | 0.170 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2021 | 210 | 0.170 |
Why?
|
| Humans | 27 | 2024 | 272039 | 0.170 |
Why?
|
| Equipment and Supplies | 1 | 2019 | 51 | 0.170 |
Why?
|
| Radiation Oncologists | 1 | 2019 | 31 | 0.170 |
Why?
|
| Space Flight | 2 | 2013 | 129 | 0.160 |
Why?
|
| Film Dosimetry | 1 | 2019 | 62 | 0.160 |
Why?
|
| Hypoxia-Inducible Factor-Proline Dioxygenases | 1 | 2019 | 48 | 0.160 |
Why?
|
| Radiobiology | 1 | 2019 | 56 | 0.160 |
Why?
|
| Indoles | 1 | 2024 | 1034 | 0.160 |
Why?
|
| Isoquinolines | 1 | 2019 | 125 | 0.160 |
Why?
|
| Radiation-Protective Agents | 1 | 2019 | 129 | 0.160 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 12016 | 0.150 |
Why?
|
| Radiopharmaceuticals | 1 | 2023 | 1338 | 0.150 |
Why?
|
| Molecular Imaging | 1 | 2019 | 186 | 0.150 |
Why?
|
| Pancreas | 1 | 2021 | 746 | 0.150 |
Why?
|
| Neck | 1 | 2020 | 392 | 0.140 |
Why?
|
| Air | 1 | 2017 | 65 | 0.140 |
Why?
|
| Chemoradiotherapy | 2 | 2016 | 2030 | 0.140 |
Why?
|
| Scintillation Counting | 1 | 2018 | 102 | 0.140 |
Why?
|
| Calcium-Binding Proteins | 1 | 2019 | 557 | 0.140 |
Why?
|
| Glycine | 1 | 2019 | 320 | 0.140 |
Why?
|
| Gene Silencing | 1 | 2019 | 834 | 0.140 |
Why?
|
| Energy Transfer | 1 | 2016 | 36 | 0.130 |
Why?
|
| Cell Tracking | 1 | 2016 | 38 | 0.130 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2024 | 3934 | 0.130 |
Why?
|
| Pyrazoles | 1 | 2024 | 1545 | 0.130 |
Why?
|
| Neoplasms | 4 | 2023 | 15914 | 0.130 |
Why?
|
| Reference Standards | 1 | 2016 | 369 | 0.120 |
Why?
|
| Sulfonamides | 1 | 2024 | 1930 | 0.120 |
Why?
|
| Models, Statistical | 2 | 2013 | 1190 | 0.120 |
Why?
|
| Liver Neoplasms | 2 | 2024 | 4816 | 0.120 |
Why?
|
| Spleen | 1 | 2016 | 731 | 0.120 |
Why?
|
| Lymphopenia | 1 | 2016 | 211 | 0.120 |
Why?
|
| Adenocarcinoma | 2 | 2023 | 7976 | 0.120 |
Why?
|
| Liver | 1 | 2024 | 3123 | 0.120 |
Why?
|
| Breast Neoplasms | 3 | 2024 | 16252 | 0.110 |
Why?
|
| Microscopy, Fluorescence | 1 | 2016 | 782 | 0.110 |
Why?
|
| Rectal Neoplasms | 1 | 2022 | 1240 | 0.110 |
Why?
|
| Quality Control | 3 | 2020 | 467 | 0.110 |
Why?
|
| Reproducibility of Results | 5 | 2019 | 6208 | 0.110 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 3026 | 0.110 |
Why?
|
| Organs at Risk | 1 | 2016 | 559 | 0.110 |
Why?
|
| Extraterrestrial Environment | 1 | 2013 | 9 | 0.110 |
Why?
|
| Cell Line | 1 | 2021 | 5433 | 0.110 |
Why?
|
| Mars | 1 | 2013 | 5 | 0.110 |
Why?
|
| Radiation | 1 | 2013 | 19 | 0.110 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2023 | 1825 | 0.100 |
Why?
|
| X-Rays | 2 | 2022 | 153 | 0.100 |
Why?
|
| Immunoassay | 1 | 2013 | 214 | 0.100 |
Why?
|
| Histones | 1 | 2019 | 1514 | 0.100 |
Why?
|
| Pyrimidines | 1 | 2024 | 3664 | 0.100 |
Why?
|
| Light | 1 | 2012 | 280 | 0.100 |
Why?
|
| Radiation Injuries | 1 | 2019 | 1472 | 0.100 |
Why?
|
| Lung | 2 | 2019 | 3299 | 0.090 |
Why?
|
| Mutation | 3 | 2021 | 15954 | 0.090 |
Why?
|
| Genetic Testing | 1 | 2019 | 1699 | 0.090 |
Why?
|
| Cells, Cultured | 1 | 2019 | 5788 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2022 | 10369 | 0.090 |
Why?
|
| Equipment Design | 3 | 2020 | 1206 | 0.080 |
Why?
|
| Cosmic Radiation | 1 | 2009 | 15 | 0.080 |
Why?
|
| Colorectal Neoplasms | 1 | 2024 | 3705 | 0.080 |
Why?
|
| BRCA1 Protein | 2 | 2021 | 522 | 0.080 |
Why?
|
| Genes, BRCA2 | 2 | 2021 | 321 | 0.080 |
Why?
|
| Bayes Theorem | 2 | 2023 | 1056 | 0.080 |
Why?
|
| DNA Repair | 3 | 2022 | 1912 | 0.080 |
Why?
|
| Models, Anatomic | 1 | 2009 | 146 | 0.080 |
Why?
|
| Uncertainty | 1 | 2010 | 329 | 0.070 |
Why?
|
| Female | 9 | 2024 | 149291 | 0.070 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2019 | 2174 | 0.070 |
Why?
|
| Mice | 2 | 2024 | 36058 | 0.060 |
Why?
|
| Neutrons | 2 | 2019 | 117 | 0.060 |
Why?
|
| Prostatic Neoplasms | 1 | 2022 | 5995 | 0.060 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2015 | 2167 | 0.060 |
Why?
|
| Radiotherapy, Conformal | 1 | 2010 | 898 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2020 | 2357 | 0.060 |
Why?
|
| Induction Chemotherapy | 2 | 2016 | 671 | 0.050 |
Why?
|
| Radioisotopes | 1 | 2023 | 177 | 0.050 |
Why?
|
| Organ Size | 1 | 2024 | 727 | 0.050 |
Why?
|
| Boron Compounds | 1 | 2022 | 69 | 0.050 |
Why?
|
| Pharmaceutical Preparations | 1 | 2023 | 157 | 0.050 |
Why?
|
| Phenylalanine | 1 | 2022 | 167 | 0.050 |
Why?
|
| Animals | 2 | 2024 | 62826 | 0.050 |
Why?
|
| Physics | 1 | 2021 | 44 | 0.050 |
Why?
|
| Biology | 1 | 2021 | 76 | 0.050 |
Why?
|
| Equipment Failure Analysis | 2 | 2013 | 327 | 0.040 |
Why?
|
| Remote Sensing Technology | 1 | 2019 | 12 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2022 | 314 | 0.040 |
Why?
|
| Germ Cells | 1 | 2021 | 351 | 0.040 |
Why?
|
| Ataxia Telangiectasia | 1 | 2019 | 62 | 0.040 |
Why?
|
| Male | 7 | 2024 | 129081 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2019 | 425 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2023 | 2610 | 0.040 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2022 | 514 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 371 | 0.040 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2019 | 231 | 0.040 |
Why?
|
| Aged | 5 | 2024 | 73500 | 0.040 |
Why?
|
| Retrospective Studies | 4 | 2022 | 39828 | 0.040 |
Why?
|
| Stochastic Processes | 1 | 2017 | 49 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2019 | 751 | 0.040 |
Why?
|
| Terminology as Topic | 1 | 2019 | 423 | 0.030 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2019 | 404 | 0.030 |
Why?
|
| Heterozygote | 1 | 2019 | 1057 | 0.030 |
Why?
|
| Syndrome | 1 | 2019 | 1407 | 0.030 |
Why?
|
| Breath Holding | 1 | 2015 | 44 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 534 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2016 | 485 | 0.030 |
Why?
|
| Consensus | 1 | 2019 | 1115 | 0.030 |
Why?
|
| DNA | 1 | 2022 | 3089 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 5194 | 0.030 |
Why?
|
| Treatment Outcome | 3 | 2021 | 33913 | 0.030 |
Why?
|
| Atrazine | 1 | 2013 | 6 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2019 | 31071 | 0.030 |
Why?
|
| Chaperonin 60 | 1 | 2013 | 47 | 0.030 |
Why?
|
| Indicators and Reagents | 1 | 2013 | 140 | 0.030 |
Why?
|
| Adult | 4 | 2024 | 81993 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 16628 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 1409 | 0.030 |
Why?
|
| Middle Aged | 4 | 2024 | 90457 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2016 | 2331 | 0.020 |
Why?
|
| Radiography | 1 | 2015 | 1994 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2019 | 2157 | 0.020 |
Why?
|
| Absorption | 1 | 2010 | 80 | 0.020 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 1387 | 0.020 |
Why?
|
| Normal Distribution | 1 | 2009 | 59 | 0.020 |
Why?
|
| Adaptation, Biological | 1 | 2009 | 48 | 0.020 |
Why?
|
| Systems Integration | 1 | 2010 | 79 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2015 | 2035 | 0.020 |
Why?
|
| Antibodies | 1 | 2013 | 819 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 1533 | 0.020 |
Why?
|
| Logistic Models | 1 | 2016 | 3464 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 3854 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2019 | 5841 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 6275 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2021 | 9484 | 0.020 |
Why?
|
| Environmental Exposure | 1 | 2010 | 288 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2022 | 5213 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 5112 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 7239 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 5756 | 0.020 |
Why?
|
| Disease Progression | 1 | 2019 | 6909 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 3671 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2022 | 13999 | 0.020 |
Why?
|
| Survival Rate | 1 | 2019 | 12547 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2019 | 5506 | 0.020 |
Why?
|
| Apoptosis | 1 | 2019 | 7842 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 10258 | 0.010 |
Why?
|
| Texas | 1 | 2010 | 6433 | 0.010 |
Why?
|
| United States | 1 | 2013 | 16033 | 0.010 |
Why?
|